Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xalatan vs Usual Care in Glaucoma
NCT00140062Phase 4Completed
- Sponsor
- Pfizer
- Start
- Feb 2002
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of latanoprost in open-angle glaucoma (OAG), pseudoexfoliative glaucoma (PEXG), pigmentary glaucoma (PG) and 1 more (2 arms), sponsored by Pfizer. Primary endpoint: Time to treatment failure at 36 months. Started Feb 2002; status: completed.
02
Drugs
latanoprost
03
Conditions
open-angle glaucoma (OAG)pseudoexfoliative glaucoma (PEXG)pigmentary glaucoma (PG)ocular hypertension
Beyond the preview
Go deeper on NCT00140062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00140062.